Form 4: Dexcom EVP Jereme Sylvain Sells Shares to Cover Tax Obligations
SEC Form 4
Executive Vice President and Chief Financial Officer of Dexcom, Jereme Sylvain, sold 745 shares of common stock on June 10, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.
Summary
- Jereme M Sylvain, Executive Vice President and Chief Financial Officer of Dexcom Inc., reported a transaction involving the sale of Dexcom's common stock on June 10, 2024.
- The sale of 745 shares was executed at a price of $115.0508 per share.
- This transaction was to cover tax withholding obligations associated with the vesting of restricted stock units (RSUs).
- Following the transaction, Sylvain directly owns 84,948 shares of Dexcom, which includes 50,549 unvested restricted stock units and 159 shares purchased through the Employee Stock Purchase Plan.
Sentiment
Score: 7
Explanation: The document reflects a routine transaction related to executive compensation and tax obligations, which is neutral to slightly positive as it indicates the executive is receiving and vesting equity.
Management Comments
- The sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the reporting person.
Industry Context
Executive stock sales for tax obligations are a common practice in publicly traded companies, especially following RSU vesting.
Comparison to Industry Standards
- Executive compensation packages often include RSUs, which vest over time and are subject to income tax.
- Companies like Medtronic, Abbott, and Boston Scientific also utilize RSUs as part of their executive compensation, and similar sell-to-cover transactions are common among their executives.
- The number of shares sold and the timing align with typical RSU vesting schedules and tax obligations.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a routine sale to cover tax obligations.
- Employees may view the vesting of RSUs as a positive aspect of the company's compensation structure.
Key Dates
| Date | Description |
|---|---|
| 12/15/2021 | Grant date for 2,924 RSUs vesting through December 15, 2024 |
| 03/08/2022 | Grant date for 7,060 RSUs vesting through March 8, 2025 |
| 03/08/2023 | Grant date for 14,512 RSUs vesting through March 8, 2026 |
| 03/08/2024 | Grant date for 26,053 RSUs vesting through March 8, 2027 |
| 06/10/2024 | Date of stock sale transaction |
| 06/11/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.